Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Jou

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|January 25, 2014
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interfaceHuameng Li, Hui Xiao, Li Lin, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|August 4, 2025
Abnormal Nuclear Membranous Staining Pattern by MLH1 Immunohistochemistry in Endometrial Cancer: A Diagnostic Pitfall and Clone-dependent ArtifactLisha Wang, David Jou, Ruchi Patel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 24, 2021
Prostatic metaplasia and pilar differentiation in gender-affirming mastectomy specimensCharlotte F Kim, David Jou, Oren Ganor, et al.
American Journal of Clinical Pathology|October 3, 2020
Impact of a Modified HistoGel Method for Processing Endocervical Curettage Specimens on Diagnostic YieldMaximiliano Ramia de Cap, David Jou, Yigu Chen, et al.
The Journal of Biological Chemistry|October 15, 2014
A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cellsHui Xiao, Hemant Kumar Bid, David Jou, et al.
Ecology|March 23, 2019
The bioelements, the elementome, and the biogeochemical nicheJosep Peñuelas, Marcos Fernández-Martínez, Philippe Ciais, et al.
The Journal of Sports Medicine and Physical Fitness|February 7, 2019
The influence of non-modifiable and modifiable factors on cardiac biomarkers after marathon runningThomas G Martin, Rachel W Pata, David Jou, et al.
International Journal of Oncology|October 18, 2016
STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cellsLi Lin, David Jou, Yina Wang, et al.
Plos One|October 12, 2012
XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cellsAiguo Liu, Yan Liu, Zhigang Jin, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
MicroRNA spatial profiling for assessing drug efficacy in <i>BRCA1</i> -related triple-negative breast tumorsOmar N Mohd, Lin Wang, Brian R Sardella, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|January 25, 2014
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interfaceHuameng Li, Hui Xiao, Li Lin, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|August 4, 2025
Abnormal Nuclear Membranous Staining Pattern by MLH1 Immunohistochemistry in Endometrial Cancer: A Diagnostic Pitfall and Clone-dependent ArtifactLisha Wang, David Jou, Ruchi Patel, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 24, 2021
Prostatic metaplasia and pilar differentiation in gender-affirming mastectomy specimensCharlotte F Kim, David Jou, Oren Ganor, et al.
American Journal of Clinical Pathology|October 3, 2020
Impact of a Modified HistoGel Method for Processing Endocervical Curettage Specimens on Diagnostic YieldMaximiliano Ramia de Cap, David Jou, Yigu Chen, et al.
The Journal of Biological Chemistry|October 15, 2014
A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cellsHui Xiao, Hemant Kumar Bid, David Jou, et al.
Ecology|March 23, 2019
The bioelements, the elementome, and the biogeochemical nicheJosep Peñuelas, Marcos Fernández-Martínez, Philippe Ciais, et al.
The Journal of Sports Medicine and Physical Fitness|February 7, 2019
The influence of non-modifiable and modifiable factors on cardiac biomarkers after marathon runningThomas G Martin, Rachel W Pata, David Jou, et al.
International Journal of Oncology|October 18, 2016
STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cellsLi Lin, David Jou, Yina Wang, et al.
Plos One|October 12, 2012
XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cellsAiguo Liu, Yan Liu, Zhigang Jin, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
MicroRNA spatial profiling for assessing drug efficacy in <i>BRCA1</i> -related triple-negative breast tumorsOmar N Mohd, Lin Wang, Brian R Sardella, et al.
Pageof 3